D2M is ISO 13485 Compliant. Our Quality System ensures that your medical product will meet the FDA's QSR and other requirements.
MAP Pharmaceuticals
Tempo® Inhaler
According to the National Headache Foundation, approximately 30 million people in the United States suffer from migraine, a chronic and debilitating neurological disorder. Most migraines last between four and 24 hours, but some last as long as three days. Published studies show that the median frequency of attack is 1.5 times per month, although approximately 25% of migraine sufferers experience one or more attacks every week. Physicians who diagnose migraine generally prescribe a class of drugs known as triptans. Triptans have three major limitations: slow onset, not broadly efficacious, and cardiovascular (and other) side effects. Physicians who find their patients are not responding to triptans, have few other treatment options that are convenient or consistent. Patients who suffer from migraine list rapid onset and long-lasting effectiveness as the attributes they seek most in a preferred therapy.
MAP Pharmaceuticals is developing an orally inhaled version of dihydroergotamine (DHE) self administered via its proprietary Tempo® inhaler to help reach this large and underserved migraine patient market. D2M engineers, engaged on the project for their experience in mechanical medical device design, executed a rigorous technical evaluation and redesign of both early prototype and pre-commercial products. The D2M engineering team’s efforts and high level of standards were instrumental in achieving consistent design performance and high client satisfaction.
Client Testimonial
"D2M has played a key role in supporting and guiding the MAP Pharmaceuticals team in meeting its development goals. They have consistently shown the kind of commitment to MAP Pharmaceuticals’ programs that we would typically expect only to come from in-house employees. D2M is a responsive, innovative, approachable and reliable resource.”
- Scott Borland, Senior Director, CNS Program and Technical Operations
The Details
Traditional self-administered drug inhalers deliver medication from a pressurized canister via the coordinated motion of canister depression and inhalation. MAP Pharmaceuticals’ Tempo inhaler is designed to eliminate this coordinated activity, which often leads to a spray of drug onto the back of the user’s mouth instead of into the lungs, and entrain the drug material into the inhaled airflow. As a result, the aim of the Tempo inhaler design is to reduce the rate of user error and consequently help increase drug effectiveness.
D2M was instrumental in improving the sealing, robustness, and design quality of older prototype designs and in developing a dose counter. We developed test fixtures and measurement setups to simultaneously evaluate and verify design performance to conform to the client’s development schedule. Our team added significant engineering value through innovative mechanism design, rigorous tolerance and risk analyses, testing, and consistent updates to the client’s Design History File.